Original expectations of the Hancock valve and 20 years of clinical reality

Eur J Cardiothorac Surg. 1992:6 Suppl 1:S75-8.

Abstract

The standard (glutaraldehyde-preserved) Hancock porcine bioprosthesis was introduced into clinical practice in order to provide surgeons with a cardiac valve substitute which would be nonthrombogenic and therefore would not require anticoagulation, and would be durable, anatomically suitable, and noiseless. In the present report we have reviewed our long-term experience with Hancock porcine valve recipients in order to verify the original expectations of this bioprosthesis have been met.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bioprosthesis / standards*
  • Child
  • Follow-Up Studies
  • Glutaral / therapeutic use
  • Heart Valve Prosthesis / standards*
  • Hospitals, University
  • Humans
  • Italy / epidemiology
  • Middle Aged
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Postoperative Complications / mortality
  • Prosthesis Failure
  • Prosthesis-Related Infections / epidemiology
  • Prosthesis-Related Infections / etiology
  • Prosthesis-Related Infections / mortality
  • Survival Rate
  • Thromboembolism / epidemiology
  • Thromboembolism / etiology
  • Thromboembolism / mortality
  • Tissue Preservation / methods

Substances

  • Glutaral